We know now that glucagon-like peptide 1 (GLP-1) drugs for obesity bring with them a whole host of other potential benefits, as well as a handful of side effects. But new research has brought a sharper focus on both the pros and the cons of these medications, and with that comes new challenges and opportunities for physicians to consider when prescribing them.
In a new study released this week in Nature Medicine, researchers studied four GLP-1 receptor agonist medications, namely, Ozempic, Zepbound, Mounjaro, and Wegovy, and identified175 possible health outcomes in 215,970 people on the medications. They then compared their health outcomes with those in 2.4 million individuals who were not on any weight loss medications.
Researchers found that outside of weight loss, patients experienced a laundry list of positive…